Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1. To evaluate the efficacy of two doses of MK-7655 + imipenem/cilastatin (250 mg and 125 mg), as compared with imipenem/cilastatin alone, with respect to the clinical response assessment profile in the treatment of adult patients with cIAI at completion of IV study therapy (DCIV). 2. To evaluate the safety and tolerability profile of two doses of MK- 7655 + imipenem/cilastatin (250 mg and 125 mg).
Critère d'inclusion
- Patients with Complicated Intra-Abdominal Infection